Dr. Linda R. Duska, MD

Dr. Duska practices at UVA University Medical Center in Charlottesville, Virginia.

Dr. Duska's NPI, 1447241807, was assigned on November 3, 2005. Dr. Duska graduated from New York University School of Medicine in 1991. Dr. Duska holds Virginia license 0101244229.

Dr. Duska's primary practice is UVA University Medical Center, at 1215 Lee St, Charlottesville, VA 22908 in Charlottesville City. The practice phone is (434) 760-3439.

Dr. Duska's primary practice is UVA University Medical Center in Charlottesville, Virginia. Dr. Duska is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Duska to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Duska practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Duska's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Duska's licenses on file in 2 states: Virginia and Massachusetts.

CMS data shows 380 Medicare services from Dr. Duska across 4 procedure codes in 2024, for 192 Medicare patients. Medicare paid $33,713 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 192 Medicare patients who saw Dr. Duska in 2024. The largest group is 65 to 74, with 96 patients. 74% of them have high blood pressure, and 68% have high cholesterol. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Duska's median patient age at 64, with 99% women.

In 2024, Dr. Duska wrote 208 Medicare Part D claims for 49 patients. 90% of them were for generic drugs. CMS names the drug for 103 of them, across 4 drugs with 11 or more claims each, at $1,231 in total drug cost. In 2023, CMS named 113 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Duska for performance year 2024, reported as part of a group. Dr. Duska accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 14 procedures of removal of the uterus by Dr. Duska, more than 88% of the clinicians it reports for that procedure.

Dmand AI links 110 papers to Dr. Duska, published from 2011 to 2025. 2019 was the busiest year, with 10. The most frequent topics are Ovarian Neoplasms, Endometrial Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Duska has published most often in Gynecol Oncol. Dr. Duska's most frequent co-authors are Leigh A. Cantrell, MD, MSPH, Jennifer Michelle Scalici, MD and Paula M. Fracasso, MD.

Dmand AI links Dr. Duska to 12 clinical trials, 3 of them phase 1 studies. 11 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Ovarian Neoplasms and Fallopian Tube Neoplasms. National Cancer Institute (NCI) sponsors the most, 7. Open Payments lists research payments to Dr. Duska that name 2 trials.

CMS Open Payments shows 87 general payments to Dr. Duska from 12 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 57% of the total. Merck Sharp & Dohme Corporation paid the most, $48,190. It also lists 12 research payments totaling $16,550 from 2016 to 2025, naming 2 clinical trials.

Dr. Duska graduated from New York University School of Medicine in 1991.